Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

Posted: January 6, 2024 at 2:37 am

If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea

Read this article:
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

Related Posts